Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

IGILUC 2019 /
Using genetic testing to tailor chemotherapy

18th - 19th Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.05.19
Views: 475

Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA

Prof Heinz-Josef Lenz speaks to ecancer at the 2019 International Gastrointestinal, Liver and Uro-Oncology Conference (IGILUC) in Cairo about using a patient's mutational profile to tailor the type of chemotherapy treatment they receive.

Prof Lenz explains the concept of genetic testing to identify genes such as RAS, B-RAF, microsatellite instability and HER2. Genetic testing can guide treatment decisions, such as determining the effectiveness of first-line chemotherapy for an individual patient.

He also describes the financial and molecular challenges associated with this type of testing, along with known predictive markers.

In the future, Prof Lenz believes all patients should be screened to enable effective personalised treatment.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation